Esperion Therapeutics, Inc. financials

ESPR CIK 0001434868

Source: EDGAR filings · Built 2026-06-02T02:56:22Z

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Free Cash Flow -13.09M -23.97M -135.49M -174.83M -263.81M -86.05M
EBITDA 60.38M 54.47M -155.40M -179.00M -226.12M -120.85M
Working Capital 161.76M 91.77M 44.84M 154.38M 255.62M 251.83M
Net Debt 84.38M 152.84M 183.92M 136.17M 51.30M -119.55M
Operating Margin 14.95% 16.37% -133.72% -237.83% -289.02% -53.35%
Net Margin -5.63% -15.57% -179.87% -309.58% -343.04% -63.09%
Return on Equity (ROE) 7.51% 13.31% 45.99% 72.17% 136.64% 149.32%
Return on Assets (ROA) -4.87% -15.05% -101.68% -94.24% -70.52% -40.64%
Current Ratio 1.54× 1.37× 1.29× 2.67× 4.48× 3.68×
Debt-to-Equity -0.84× -0.77× -0.58× -0.81× -1.32× -1.93×
Effective Tax Rate -8.83% 0.00% 0.00%
Cash Conversion Ratio 0.58× 0.46× 0.65× 0.75× 0.98× 0.59×
Accruals Ratio -0.02× -0.08× -0.36× -0.24× -0.01× -0.17×
SBC % of Revenue 2.45% 3.61% 10.28% 20.16% 30.98% 12.47%
CapEx Coverage -74.62× -98.02×
Free Cash Flow Per Share $-0.06 $-0.13 $-1.31 $-2.63 $-9.13 $-3.13

Valuation Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
EV / EBITDA 16.55× 10.80×
P/S 2.27× 1.31× 3.09× 6.32× 4.01× 3.19×

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Revenue from Contract with Customer, Excluding Assessed Tax 403.13M 332.31M 116.33M 75.47M 78.45M 227.55M
Selling, General and Administrative Expense 165.79M 163.07M 142.52M 109.08M 184.99M 199.62M
Operating Expenses 342.86M 277.91M 271.90M 254.98M 305.18M 348.94M
Operating Income (Loss) 60.27M 54.40M -155.56M -179.50M -226.73M -121.40M
Income Tax Expense (Benefit) 1.84M 0 0 0 0 0
Net Income (Loss) Attributable to Parent -22.68M -51.74M -209.25M -233.66M -269.11M -143.55M
Earnings Per Share, Basic $-0.11 $-0.28 $-2.03 $-3.52 $-9.31 $-5.23
Weighted Average Number of Shares Outstanding, Basic 207.87M 187.18M 103.11M 66.41M 28.90M 27.47M
Earnings Per Share, Diluted $-0.11 $-0.28 $-2.03 $-3.52 $-9.31 $-5.23
Weighted Average Number of Shares Outstanding, Diluted 207.87M 187.18M 103.11M 66.41M 28.90M 27.47M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Cash and Cash Equivalents, at Carrying Value 167.85M 144.76M 82.25M 124.78M 208.89M 304.96M
Assets, Current 462.57M 338.00M 201.06M 246.68M 328.97M 345.90M
Assets 465.89M 343.82M 205.80M 247.94M 381.59M 353.26M
Liabilities, Current 300.81M 246.23M 156.22M 92.31M 73.35M 94.07M
Liabilities 767.85M 732.54M 660.79M 571.72M 578.53M 449.39M
Stockholders' Equity Attributable to Parent -301.96M -388.72M -454.99M -323.78M -196.94M -96.13M

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Net Cash Provided by (Used in) Operating Activities -13.09M -23.65M -135.49M -174.83M -263.81M -85.18M
Payments to Acquire Property, Plant, and Equipment 0 317.00K 0 0 0 869.00K
Net Cash Provided by (Used in) Investing Activities 0 -317.00K 42.50M 8.10M -50.48M 21.36M
Payments for Repurchase of Common Stock 0 55.00M
Net Cash Provided by (Used in) Financing Activities 36.18M 86.48M 50.46M 32.61M 268.22M 201.72M

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (ESPR CIK 0001434868), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

CTSO

CYTOSORBENTS CORPORATION

MIRM

Mirum Pharmaceuticals, Inc.

TYRA

TYRA BIOSCIENCES, INC.